CTRI/2023/12/060891进行中（未招募）1 期
A Randomized, Placebo-Controlled, Interventional Study to evaluate the effectiveness and safety of nosodes sourced from E. coli, S. typhi, K. pneumonia, and Hepatitis C biomaterials in Healthy Study Participants. - NI
Biosimilia Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Males and non-pregnant, non-lactating females between 18-65 years of age; inclusive at the time of signing the Informed Consent.
- •2.Willing and able to provide written informed consent prior to any study-specific procedures being performed.
- •3.Study participant is willing to be available for the entire study period and to adhere to protocol requirements as evidenced by signing informed consent document.
- •4.Study participants with no known history of E. coli or S. typhi or K. pneumonia or Hepatitis C infection 03 months prior to screening.
- •5.Judged by an investigator to be in good health as documented by the medical history, physical examination (including but may not be limited to an evaluation of the cardiovascular, gastrointestinal, respiratory, and central nervous systems), vital sign assessments, clinical laboratory assessments, and by general observations. Any abnormalities or deviations outside the normal ranges for any clinical testing (laboratory tests, vital signs) can be repeated at the discretion of the investigator(s) and judged to be not clinically significant for study participation.
- •6.Body mass index (BMI) between 18.5 kg/m2 to 24.9 kg/m2, inclusive for study participants calculated as (weight in kg) / (height in m)2 and weigh at least 50 kg.
- •7.Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria:
- •-Has a negative pregnancy test at screening and on the day of randomization (Day 1).
- •-Is not currently breastfeeding.
- •Has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to randomization (Day 1).
- •-Has agreed to continue adequate contraception through 3 months following the last dose.
- •Adequate female contraception is defined as consistent and correct use of a Food and Drug Administration (FDA) approved contraceptive method in accordance with the product label. For example: Barrier method (such as condoms, diaphragm, or cervical cap) used in conjunction with spermicide; intrauterine device; prescription hormonal contraceptive taken or administered via oral (pill), transdermal (patch), subdermal, or IM route; sterilization of a female participant’s monogamous male partner prior to entry into the study.
- •[Note: periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.]
排除标准
- •1.Reports a history of allergic response(s) to the active ingredient or to any of the excipients of the Investigational homeopathic product.
- •2.Pregnant and Lactating Female.
- •3.Prior administration of E. coli or S. typhi or K. pneumonia or Hepatitis C vaccine or current/planned simultaneous participation in another interventional study.
- •4. Reports receiving any investigational drug within 90 days prior to randomization.
- •5.Demonstrates, in the opinion of study staff, veins unsuitable for repeated venipuncture (e.g., veins difficult to locate, access, or puncture; veins with a tendency to rupture during or after puncture).
- •6.Positive test results for E. coli or S. typhi or K. pneumonia or Hepatitis C antibodies.
- •7.Study participants had a known history of allergies or food hypersensitivity.
- •8.Unable to understand aims and constraints of study and complete self-evaluation study participant diary.
- •9. Other conditions, which in the opinion of the investigators make the study participants unsuitable for enrolment or could interfere with adherence to the study protocol.
研究者
相似试验
进行中（未招募）
1 期
A double-blind, placebo-controlled, interventional parallel group study to evaluate the antiviral effect of a single nasal application of LTX-109 3% gel, in comparison to placebo gel, in subjects with COVID-19 infectioCOVID-19MedDRA version: 23.1Level: LLTClassification code 10084401Term: COVID-19 respiratory infectionSystem Organ Class: 100000004862EUCTR2021-000455-39-SEPharma Holdings AS60
已完成
2 期
Fish Oils (Omega 3) in ischaemic strokeIschaemic Cerebrovascular DiseaseIschaemic Cerebrovascular StrokeStroke - IschaemicACTRN12605000207617Health Research Council (New Zealand)220
招募中
3 期
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive BladderCTRI/2009/091/000360Allergan, Inc.135
进行中（未招募）
不适用
A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respiratory ImpairmentPatients with urinary incontinence due to neurogenic detrusor overactivity as a result of spinal cord injury or multiple sclerosis who have not been adequately managed with anticholinergic therapy and have neurological respiratory impairment.MedDRA version: 8.1Level: LLTClassification code 10046543Term: Urinary incontinenceEUCTR2006-006299-39-NLAllergan135
进行中（未招募）
1 期
A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respiratory ImpairmentPatients with urinary incontinence due to neurogenic detrusor overactivity as a result of spinal cord injury or multiple sclerosis who have not been adequately managed with anticholinergic therapy and have neurological respiratory impairment.MedDRA version: 8.1Level: LLTClassification code 10046543Term: Urinary incontinenceEUCTR2006-006299-39-FRAllergan135